Kyowa Kirin Co ((KYKOF)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Kyowa Kirin Co. is conducting a Phase 2 clinical study titled A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration. The study aims to evaluate the efficacy and safety of KHK4951 eye drops in treating neovascular age-related macular degeneration (nAMD), a significant cause of vision loss.
The intervention involves testing KHK4951, a vascular endothelial growth factor receptor inhibitor, administered as eye drops. The study also includes Aflibercept injections, which are standard treatments for nAMD, to compare efficacy.
This interventional study is randomized with a parallel assignment model. It employs a quadruple masking approach, meaning participants, care providers, investigators, and outcomes assessors are blinded to the treatment allocation. The primary purpose is treatment-focused.
The study began on October 31, 2023, with primary completion expected by June 4, 2025. These dates are crucial for tracking the study’s progress and anticipating results that could influence market dynamics.
The study’s progress could significantly impact Kyowa Kirin’s stock performance, as positive outcomes may enhance investor confidence and market position in the competitive nAMD treatment landscape. Competitors in the field may also feel pressure to innovate or adjust strategies.
The study is currently recruiting, with updates available on the ClinicalTrials portal.